Sign in

    James Birchenough

    Research Analyst at Wells Fargo Securities, LLC

    James Birchenough is Vice Chairman of Wells Fargo Corporate and Investment Banking and head of biopharma investment banking, specializing in advising biopharmaceutical companies ranging from early stage startups to large pharma enterprises. He has provided equity research and investment advice for over 100 biotechnology firms, including Global Blood Therapeutics, Beam Therapeutics, Editas, Bluebird Bio, and Sangamo, and is recognized for his extensive coverage and expertise in genetic diseases. Birchenough began his finance career after practicing medicine, holding senior equity analyst roles at Lehman Brothers, Barclays, BMO Capital Markets, and Wells Fargo, and became Vice Chairman at Wells Fargo in March 2021 before moving to Barclays in late 2023. He holds a medical doctorate from McMaster University, is FINRA-registered, and is regarded as a top-performing analyst and leader in biopharma investment banking.

    James Birchenough's questions to SNSS leadership

    James Birchenough's questions to SNSS leadership • Q4 2016

    Question

    James Birchenough of Wells Fargo Securities, LLC asked for specifics on the SNS-062 binding site and its competitive differentiation, and whether the initial trial patients would be ibrutinib failures with the C481S mutation.

    Answer

    President and CEO Daniel Swisher explained that SNS-062 binds away from the C481S mutation site, preserving its efficacy, and noted their lead position among non-covalent inhibitors. VP of Clinical Development Linda Neuman confirmed the trial will enroll patients who have failed a prior BTK inhibitor, anticipating most will have the C481S mutation.

    Ask Fintool Equity Research AI